170 related articles for article (PubMed ID: 36431901)
1. Identification of Dihydrolipoamide Dehydrogenase as Potential Target of Vemurafenib-Resistant Melanoma Cells.
Tabolacci C; Giordano D; Rossi S; Cordella M; D'Arcangelo D; Moschella F; D'Atri S; Biffoni M; Facchiano A; Facchiano F
Molecules; 2022 Nov; 27(22):. PubMed ID: 36431901
[TBL] [Abstract][Full Text] [Related]
2. The positive correlation between drug addiction and drug dosage in vemurafenib-resistant melanoma cells is underpinned by activation of ERK1/2-FRA-1 pathway.
Rao M; Shi B; Yuan Y; Wang Y; Chen Y; Liu X; Li X; Zhang M; Liu X; Sun X
Anticancer Drugs; 2020 Nov; 31(10):1026-1037. PubMed ID: 32868647
[TBL] [Abstract][Full Text] [Related]
3. Indoleamine 2,3-dioxygenase in melanoma progression and BRAF inhibitor resistance.
Sandri S; Watanabe LRM; Oliveira EA; Faião-Flores F; Migliorini S; Tiago M; Felipe-Silva A; Vazquez VL; da Costa Souza P; Consolaro MEL; Campa A; Maria-Engler SS
Pharmacol Res; 2020 Sep; 159():104998. PubMed ID: 32535222
[TBL] [Abstract][Full Text] [Related]
4. Silencing FLI or targeting CD13/ANPEP lead to dephosphorylation of EPHA2, a mediator of BRAF inhibitor resistance, and induce growth arrest or apoptosis in melanoma cells.
Azimi A; Tuominen R; Costa Svedman F; Caramuta S; Pernemalm M; Frostvik Stolt M; Kanter L; Kharaziha P; Lehtiö J; Hertzman Johansson C; Höiom V; Hansson J; Egyhazi Brage S
Cell Death Dis; 2017 Aug; 8(8):e3029. PubMed ID: 29048432
[TBL] [Abstract][Full Text] [Related]
5. Mortalin depletion induces MEK/ERK-dependent and ANT/CypD-mediated death in vemurafenib-resistant B-Raf
Wu PK; Hong SK; Park JI
Cancer Lett; 2021 Apr; 502():25-33. PubMed ID: 33440231
[TBL] [Abstract][Full Text] [Related]
6. Identification of the Serine Biosynthesis Pathway as a Critical Component of BRAF Inhibitor Resistance of Melanoma, Pancreatic, and Non-Small Cell Lung Cancer Cells.
Ross KC; Andrews AJ; Marion CD; Yen TJ; Bhattacharjee V
Mol Cancer Ther; 2017 Aug; 16(8):1596-1609. PubMed ID: 28500236
[TBL] [Abstract][Full Text] [Related]
7. Proteogenomics Reveals Perturbed Signaling Networks in Malignant Melanoma Cells Resistant to BRAF Inhibition.
Schmitt M; Sinnberg T; Bratl K; Zittlau K; Garbe C; Macek B; Nalpas NC
Mol Cell Proteomics; 2021; 20():100163. PubMed ID: 34673281
[TBL] [Abstract][Full Text] [Related]
8. Targeting the hedgehog transcription factors GLI1 and GLI2 restores sensitivity to vemurafenib-resistant human melanoma cells.
Faião-Flores F; Alves-Fernandes DK; Pennacchi PC; Sandri S; Vicente AL; Scapulatempo-Neto C; Vazquez VL; Reis RM; Chauhan J; Goding CR; Smalley KS; Maria-Engler SS
Oncogene; 2017 Mar; 36(13):1849-1861. PubMed ID: 27748762
[TBL] [Abstract][Full Text] [Related]
9. HI-511 overcomes melanoma drug resistance
Chang X; Zhang T; Wang Q; Rathore MG; Reddy K; Chen H; Shin SH; Ma WY; Bode AM; Dong Z
Theranostics; 2020; 10(21):9721-9740. PubMed ID: 32863956
[No Abstract] [Full Text] [Related]
10. Characterization of Vemurafenib-Resistant Melanoma Cell Lines Reveals Novel Hallmarks of Targeted Therapy Resistance.
Radić M; Vlašić I; Jazvinšćak Jembrek M; Horvat A; Tadijan A; Sabol M; Dužević M; Herak Bosnar M; Slade N
Int J Mol Sci; 2022 Aug; 23(17):. PubMed ID: 36077308
[TBL] [Abstract][Full Text] [Related]
11. Role of VEGFR-1 in melanoma acquired resistance to the BRAF inhibitor vemurafenib.
Atzori MG; Ceci C; Ruffini F; Trapani M; Barbaccia ML; Tentori L; D'Atri S; Lacal PM; Graziani G
J Cell Mol Med; 2020 Jan; 24(1):465-475. PubMed ID: 31758648
[TBL] [Abstract][Full Text] [Related]
12. Targeting Extracellular Matrix Remodeling Restores BRAF Inhibitor Sensitivity in BRAFi-resistant Melanoma.
Marusak C; Thakur V; Li Y; Freitas JT; Zmina PM; Thakur VS; Chang M; Gao M; Tan J; Xiao M; Lu Y; Mills GB; Flaherty K; Frederick DT; Miao B; Sullivan RJ; Moll T; Boland GM; Herlyn M; Zhang G; Bedogni B
Clin Cancer Res; 2020 Nov; 26(22):6039-6050. PubMed ID: 32820016
[TBL] [Abstract][Full Text] [Related]
13. miR-7 reverses the resistance to BRAFi in melanoma by targeting EGFR/IGF-1R/CRAF and inhibiting the MAPK and PI3K/AKT signaling pathways.
Sun X; Li J; Sun Y; Zhang Y; Dong L; Shen C; Yang L; Yang M; Li Y; Shen G; Tu Y; Tao J
Oncotarget; 2016 Aug; 7(33):53558-53570. PubMed ID: 27448964
[TBL] [Abstract][Full Text] [Related]
14. Overcoming acquired BRAF inhibitor resistance in melanoma via targeted inhibition of Hsp90 with ganetespib.
Acquaviva J; Smith DL; Jimenez JP; Zhang C; Sequeira M; He S; Sang J; Bates RC; Proia DA
Mol Cancer Ther; 2014 Feb; 13(2):353-63. PubMed ID: 24398428
[TBL] [Abstract][Full Text] [Related]
15. Reactivation of mitogen-activated protein kinase (MAPK) pathway by FGF receptor 3 (FGFR3)/Ras mediates resistance to vemurafenib in human B-RAF V600E mutant melanoma.
Yadav V; Zhang X; Liu J; Estrem S; Li S; Gong XQ; Buchanan S; Henry JR; Starling JJ; Peng SB
J Biol Chem; 2012 Aug; 287(33):28087-98. PubMed ID: 22730329
[TBL] [Abstract][Full Text] [Related]
16. Metabolic imaging using hyperpolarized
Acciardo S; Mignion L; Lacomblez E; Schoonjans C; Joudiou N; Gourgue F; Bouzin C; Baurain JF; Gallez B; Jordan BF
J Cell Mol Med; 2020 Jan; 24(2):1934-1944. PubMed ID: 31833658
[TBL] [Abstract][Full Text] [Related]
17. Differential expression of ABCB5 in BRAF inhibitor-resistant melanoma cell lines.
Xiao J; Egger ME; McMasters KM; Hao H
BMC Cancer; 2018 Jun; 18(1):675. PubMed ID: 29929490
[TBL] [Abstract][Full Text] [Related]
18. Vemurafenib resistance signature by proteome analysis offers new strategies and rational therapeutic concepts.
Paulitschke V; Berger W; Paulitschke P; Hofstätter E; Knapp B; Dingelmaier-Hovorka R; Födinger D; Jäger W; Szekeres T; Meshcheryakova A; Bileck A; Pirker C; Pehamberger H; Gerner C; Kunstfeld R
Mol Cancer Ther; 2015 Mar; 14(3):757-68. PubMed ID: 25612618
[TBL] [Abstract][Full Text] [Related]
19. EGFR/uPAR interaction as druggable target to overcome vemurafenib acquired resistance in melanoma cells.
Laurenzana A; Margheri F; Biagioni A; Chillà A; Pimpinelli N; Ruzzolini J; Peppicelli S; Andreucci E; Calorini L; Serratì S; Del Rosso M; Fibbi G
EBioMedicine; 2019 Jan; 39():194-206. PubMed ID: 30611716
[TBL] [Abstract][Full Text] [Related]
20. Mitochondrial oxidative stress is the Achille's heel of melanoma cells resistant to Braf-mutant inhibitor.
Corazao-Rozas P; Guerreschi P; Jendoubi M; André F; Jonneaux A; Scalbert C; Garçon G; Malet-Martino M; Balayssac S; Rocchi S; Savina A; Formstecher P; Mortier L; Kluza J; Marchetti P
Oncotarget; 2013 Nov; 4(11):1986-98. PubMed ID: 24161908
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
